pyrroles has been researched along with vidarabine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delavault, P; Fegan, CD; Hambly, RM; Pepper, CJ; Thurston, DE | 1 |
| Delavault, P; Fegan, C; Hartley, JA; Lowe, H; Pepper, C; Thurieau, C; Thurston, DE | 1 |
| Browne, PV; Butini, S; Campiani, G; Catherwood, MA; Greene, LM; Hayat, A; Lawler, M; Maginn, EN; McElligott, AM; McGuckin, S; Vandenberghe, E; Williams, DC; Zisterer, DM | 1 |
| Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L | 1 |
1 trial(s) available for pyrroles and vidarabine
| Article | Year |
|---|---|
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine | 2015 |
3 other study(ies) available for pyrroles and vidarabine
| Article | Year |
|---|---|
The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Topics: Apoptosis; B-Lymphocytes; Benzodiazepines; Benzodiazepinones; Case-Control Studies; Caspase 3; Caspases; Cross-Linking Reagents; DNA Damage; DNA Repair; Enzyme Activation; Humans; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrroles; T-Lymphocytes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cross-Linking Reagents; DNA; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrroles; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2007 |
The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Caspase 8; DNA (Cytosine-5-)-Methyltransferases; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunoblotting; Immunoglobulin Heavy Chains; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microtubules; Middle Aged; Oxazepines; Prognosis; Pyrroles; Tubulin; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2009 |